Increased PD-1+ NK Cell Subset in the Older Population

Int J Gen Med. 2024 Feb 26:17:651-661. doi: 10.2147/IJGM.S452476. eCollection 2024.

Abstract

Background: The aging of the immune system is associated with various diseases. It is worth exploring the changes of the immune system in aging. Previous studies have shown that aged T cells have enhanced expression of co-inhibitory molecules. However, it remains unclear whether aged NK cells exhibit similar characteristics to aged T cells. The objective of our research was to clarify this aspect.

Patients and methods: This study included 98 adults aged 24-90 years (50 males and 48 females). We detected the subset of peripheral blood NK cells and the expression of various receptors on NK cells among donors of different age groups by flow cytometry. Immune subsets were initially defined by forward and side-scatter characteristics and then staining with the appropriate marker.

Results: The absolute number and subset distribution of NK cells were not associated with age. However, CD57 expression and CD69 expression were correlated with age. Furthermore, we found that PD-1 was up-regulated on NK cells in older people, associated with aging, while no such change was observed in other co-inhibitory molecules, including 2B4, CTLA-4, TIM-3, BTLA, CD70, CD39, CD160, and TIGIT. PD-1+ NK cells expressed high levels of CD57 and CD69, indicating PD-1+ NK cells displayed a phenotype of over-activation and aging.

Discussion: This study indicated that PD-1+ NK cells were one of the characteristics of NK cells in older people.

Conclusion: This study indicated that PD-1+ NK cells were one of the characteristics of NK cells in older people. Those findings provided new ideas to explore the underlying drivers of NK aging.

Keywords: NK cell; PD-1; aging; co-inhibitory molecules.

Grants and funding

This work was supported by the National Natural Science Foundation of China (82371565), Beijing Natural Science Foundation (M21007), Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20191802) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX202126).